| CONTACTS: |
César García,
President and Chief Executive Officer |
|
818-709-1244 x 7123
|
|
-or-
|
|
Ron Stabiner, The Wall Street Group, Inc. |
|
212-888-4848 |
CHATSWORTH, Calif. & ST. LOUIS, Mo., July 31, 2007 - IRIS International, Inc. (NASDAQ: IRIS) and Amerinet, Inc.,
a leading national health care purchasing organization, servicing more than 22,000 facilities nationwide, today announced that they have entered into a three-year sales and service supply agreement for the
first time for the entire IRIS urinalysis product line.
The agreement, which went into effect on June 1, 2007 calls for Iris Diagnostics to supply Amerinet and its member organizations with the full array of IRIS urinalysis products,
including the iQ®200 Series Urine Microscopy Analyzers, the iChem®100 Semi-Automated Urine Chemistry Analyzers, the iQ® Body Fluids Modules, along with
consumables and service contracts.
"This is a comprehensive supply agreement for sales and services with one of the largest GPOs in the country, opening a new sales channel which gives us access to more than
2,100 acute care facilities and more than 20,000 non-acute care facilities in the Amerinet network," stated IRIS President and Chief Executive Officer César García. "This latest agreement,
when combined with our other existing GPO agreements, provides IRIS entré to more than 75 percent of hospitals nationwide. We look forward to working closely with Amerinet to ensure that our products
help to deliver superior patient care at lower cost."
ABOUT AMERINET, INC.
Through Total Spend Management solutions, Amerinet strategically partners with health care providers to improve operating margins by creating efficiencies, reducing costs and
identifying new revenue streams. Supported by a team of clinical, data and supply chain experts, Amerinet offers a suite of tools, programs and services including a comprehensive and competitive portfolio
that delivers practical solutions to address members' specific needs. Based in St. Louis, Mo., with offices in Salt Lake City, Utah, Providence, R.I., and Warrendale, Pa., Amerinet serves more than
22,000 acute and non-acute health care providers nationwide. To learn more, visit www.amerinet-gpo.com.
ABOUT IRIS INTERNATIONAL, INC.
IRIS International, Inc. (www.proiris.com), based in Chatsworth, Calif., is a leading developer, manufacturer, and marketer of
medical devices, diagnostic systems and consumables. The Iris Diagnostics Division (www.irisdiagnostics.com) is a leader in automated
urinalysis technology with systems in major medical institutions throughout the world. The Company's Sample Processing business unit (formerly the StatSpin® subsidiary)
(www.statspin.com), based in Westwood, Mass., manufactures innovative centrifuges and blood analysis products. The Iris Molecular Diagnostics (IMD)
Subsidiary, based in San Diego, Calif., develops innovative ultra-sensitive diagnostics and sample processing products with applications in the urinalysis, oncology and infectious disease markets.
SAFE HARBOR PROVISION
This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include, but are not limited to, the Company's intent to monetize the ADIR technology, and are generally identified by phrases such as "thinks," "anticipates,"
"believes," "estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are
inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. Examples of forward-looking statements in this new release
include the Company's scheduled launch of its new product offerings and anticipated receipt of governmental approvals. These statements are based upon, among other things, assumptions made by, and
information currently available to, management, including management's own knowledge and assessment of the Company's industry, R&D initiatives, competition and capital requirements, and the
timing of obtaining necessary governmental approvals for its new product offerings. These and other risks are more fully described in the Company's filings with the Securities and Exchange Commission,
including the Company's most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q, which should be read in conjunction herewith for a further discussion of important factors
that could cause actual results to differ materially from those in the forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
